Evidence map›Paper›PMID 37274334›Full record

ArticleFrontiers in endocrinology2023

High carrier frequency of a nonsense p.Trp230* variant in

Nina Makretskaya, Natalia Kalinchenko, Inna Tebieva, Sofya Ionova, Rena Zinchenko, Andrey Marakhonov, Anatoly Tiulpakov

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. The frequent variant A57F in theFrontiers in genetics · 2024
    Article
  2. Editorial: Insights in adrenal endocrinology: 2023.Frontiers in endocrinology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nina MakretskayaDepartment of Genetics of Endocrine Diseases, Research Centre for Medical Genetics, Moscow, Russia.
Natalia KalinchenkoInstitute of Pediatric Endocrinology, Endocrinology Research Centre, Moscow, Russia.
Inna TebievaConsulting and Diagnostic Department, Republic of North Ossetia-Alania (RNOA) "Republican Children's Clinical Hospital", Vladikavkaz, Russia.
Sofya IonovaDepartment of Genetics of Endocrine Diseases, Research Centre for Medical Genetics, Moscow, Russia.
Rena ZinchenkoDepartment of Genetics of Endocrine Diseases, Research Centre for Medical Genetics, Moscow, Russia.
Andrey MarakhonovDepartment of Genetics of Endocrine Diseases, Research Centre for Medical Genetics, Moscow, Russia.
Anatoly TiulpakovDepartment of Genetics of Endocrine Diseases, Research Centre for Medical Genetics, Moscow, Russia.
Research Centre for Medical Genetics · RUEndocrinology Research Center · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Congenital adrenal hyperplasia (CAH) caused by 3β-HSD deficiency is a rare form of congenital adrenal deficiency with an autosomal recessive type of inheritance. Previously we have demonstrated that a single nucleotide variant (SNV) p.Trp230* in the homozygous state is a frequent cause of CAH among the indigenous population of North Ossetia-Alania represented by Ossetians. Methods: Genotyping of the NM_000198.3:c.690G>A p.Trp230* variant was performed by Real-time PCR. 339 healthy individuals of Ossetian origin were included in the study. Allele frequencies, Fisher's confidence intervals (CI) were calculated using the WinPepi v. 11.65 software. Comparison of allele frequencies was performed with the z-score test for two proportions. Results: Eight heterozygous carriers of c.690G>A variant in HSD3B2 gene were detected in 339 samples investigated. The total allele frequency of p.Trp230* variant was 0.0118 (n=8/678, 95% CI=0.0051-0.0231). Accordingly, the heterozygous carrier rate was 0.0236 (n=8/339). The frequency of CAH caused by p.Trp230* variant in HSD3B2 in Ossetian population was 1:7183 or 13.9 per 100,000 (95% CI: 1:1874-1:38447 or 3-53 per 100,000). Conclusion: The results demonstrate high frequency of p.Trp230* variant in Ossetians, which is most likely attributed to a founder effect.

Indexed as

Adrenal Hyperplasia, CongenitalProgesterone ReductaseEastern European PeopleHomozygoteHumans3 beta-hydroxysteroid dehydrogenase type IIProgesterone ReductaseCAHdeficiency of 3β-hydroxysteroid dehydrogenaseHSD3B2Ossetiansreal-time PCR

Identifiers

PMID37274334
PMCPMC10236362
OpenAlexW4376891370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.